Edward Benz

Edward J.
Benz is Vice Chairman at The Mount Desert Island Biological Laboratory, Director at F-Star Biotechnologische Forschungs-.
Und Entwicklungsges MBH, Executive Director-Cure Sickle Cell Initiative at the National Institutes of Health, Director at The Rockefeller University, Director at Mount Desert Island Hospital, Inc., Director at Massachusetts Life Sciences Center since 2011, Independent Director at Candel Therapeutics, Inc. since 2017, Director at F-star Biotechnology Ltd. since 2020, Director at Knowledge to Practice, Inc. since 2015, Director at Renovacor Holdings, Inc. since 2017, Independent Director at Renovacor, Inc. since 2017, Director at CoRegen, Inc., Advisor at Riverside Partners LLC, and Trustee at Dana-Farber.
Former positions include President, Chief Executive Officer & Director at Dana-Farber Cancer Institute, Inc. from 2000 to 2016, Chief Executive Officer at Partners Cancercare, Chairman-Medicine Department & Professor at The Johns Hopkins University School of Medicine from 1995 to 2000, Director at Dana-Farber from 2000 to 2016, Director at F-Star Therapeutics, Inc. (United States), Director at Xenetic Biosciences, Inc. from 2016 to 2017, Independent Director at F-star Therapeutics, Inc. from 2019 to 2023, Independent Director at Deciphera Pharmaceuticals, Inc. from 2019 to 2024, President of the American Society of Hematology, President of the American Society for Clinical Investigation, Dean at Harvard Medical School in 2000, President of the Association of American Cancer Institutes, Associate Editor of the New England Journal of Medicine, President of Friends of The National Institute of Nursing Research, and President of the American Clinical & Climatological Association.
Education includes graduate studies at Yale University, undergraduate degree from Princeton University in 1968, and a doctorate from Harvard Medical School.